Skip to main content
. Author manuscript; available in PMC: 2013 Nov 27.
Published in final edited form as: J Mol Cell Cardiol. 2010 Jan 29;48(6):10.1016/j.yjmcc.2010.01.014. doi: 10.1016/j.yjmcc.2010.01.014

Figure 6.

Figure 6

FGFR1 activation, as measured by phosphorylation state, in DMSO- and PD173074-treated NTg and human 24 kDa HMW Tg mouse hearts. (A) There was a significant decrease in FGFR1 phosphorylation in the PD173074-treated NTg group compared to its vehicle (DMSO)-treated cohorts; whereas, there was no difference in the FGFR1 phosphorylation state in vehicle (DMSO)-treated and PD173074-treated HMW Tg groups. (B) FGFR1 expression was not different in vehicle (DMSO)- and PD173074-treated NTg and FGF2 24 kDa HMW Tg hearts following I/R injury. n= 6 for NTg, n=9 for 24 kDa HMW Tg line 20, and n=6 for 24 kDa HMW Tg line 28. *p<0.05 vs. vehicle (DMSO)-treated cohort. #p<0.05 vs. NTg.